{
    "clinical_study": {
        "@rank": "87307", 
        "arm_group": {
            "arm_group_label": "VSLI plus rituximab", 
            "arm_group_type": "Experimental", 
            "description": "VSLI (vincristine sulfate liposome injection) plus rituximab"
        }, 
        "brief_summary": {
            "textblock": "This was a Phase 1/2 study performed at two clinical centers in the US and UK.  It was a\n      single arm, open label study evaluating VSLI plus rituximab in adults with aggressive\n      relapsed or refractory non-Hodgkin's lymphoma."
        }, 
        "brief_title": "Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL", 
        "completion_date": {
            "#text": "April 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Non-Hodgkin's Lymphoma", 
            "Diffuse Large B-cell Lymphoma", 
            "Mantle Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary efficacy endpoint was objective response rate, defined as the proportion of\n      patients with a response of CR + PR.\n\n      Duration of response, time to progression, and overall survival were analyzed. Descriptive\n      statistics were used for demographics, disease characteristics, treatment exposures,\n      efficacy, and safety variables."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically-confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL), as\n             defined by the Revised European American Lymphoma/WHO classification. This included:\n             diffuse large B-cell, primary mediastinal large B-cell lymphoma with\n             sclerosis,intravascular large B-cell lymphoma, immunoblastic B-cell lymphoma, T-cell\n             rich B-cell lymphoma or anaplastic large B-cell lymphoma. In the US protocol only,\n             patients who had transformation from an indolent lymphoma and those who had mantle\n             cell lymphoma were eligible.\n\n               -  Confirmation of CD20 expression on lymphoma cells.\n\n               -  Eastern Cooperative Oncology Group (ECOG) \u22642.\n\n               -  One or more prior chemotherapy regimens. Patients who had received prior\n                  rituximab therapy as part of an induction chemotherapy regimen or who had a\n                  previous response to rituximab as a single agent were eligible.\n\n               -  Measurable disease in at least 1 site, which had not been previously irradiated.\n\n        Measurable disease was defined as at least 1 bidimensionally measurable lesion with\n        clearly defined margins that were \u22651.5 cm in the largest dimension determined by physical\n        examination or computed tomography (CT) scan.\n\n          -  Total bilirubin and serum creatinine \u22642 times the ULN.\n\n          -  Absolute neutrophil count (ANC) \u22650.5 \u00d7 109/L, and platelets \u226550 \u00d7 109/L.\n\n          -  18 years of age or older.\n\n          -  Women of childbearing potential who were willing to use an acceptable method of\n             contraception throughout the course of the study.\n\n        Signed and dated informed consent form.\n\n        Exclusion Criteria:\n\n          -  Known transformation from an indolent lymphoma (UK protocol only).\n\n          -  Eligible for conventional or high-dose chemotherapy with curative intent.\n\n          -  Radiotherapy, chemotherapy, immunotherapy, or corticosteroids (>10 mg/day of\n             prednisone or equivalent) within the past 4 weeks.\n\n          -  Any previous malignancies with less than a 5-year complete remission interval, except\n             for curatively resected basal cell carcinoma or curatively resected in situ carcinoma\n             of the uterine cervix.\n\n          -  History of or active CNS-lymphoma, AIDS-related lymphoma, or any uncontrolled severe\n             medical illness or infection.\n\n          -  History of neurologic disorders unrelated to chemotherapy (including familial\n             neurologic diseases and acquired demyelinating disorders).\n\n          -  Grade 3 or 4 sensory or motor neuropathy at screening related to prior chemotherapy.\n\n          -  Major surgery (excluding that for diagnosis) within 4 weeks of enrollment.\n\n          -  Pregnant or lactating women (women of childbearing potential underwent a pregnancy\n             test).\n\n          -  Allergy to vincristine, or other vinca alkaloids.\n\n          -  Progressive disease while receiving or within 1 month of having received previous\n             rituximab therapy (US protocol only).\n\n          -  Hypersensitivity to any component of rituximab or to murine proteins (UK protocol\n             only)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851551", 
            "org_study_id": "CA00005"
        }, 
        "intervention": {
            "arm_group_label": "VSLI plus rituximab", 
            "intervention_name": "Vincristine Sulfate Liposome Injection plus rituximab", 
            "intervention_type": "Drug", 
            "other_name": [
                "Marqibo", 
                "VSLI", 
                "rituximab", 
                "rituxan"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vincristine", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NHL", 
            "non-Hodgkin's lymphoma", 
            "diffuse large b-cell lymphoma", 
            "mantle cell lymphoma"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "University of California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "West Yorkshire", 
                        "zip": "LS1 3EX"
                    }, 
                    "name": "Leeds General Infirmary"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Study of Rituximab Plus Vincristine Sulfate Liposomes Injection in the Treatment of Relapsed or Refractory Aggressive Non Hodgkin's Lymphoma", 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Lawrence Kaplan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Leeds General Infirmary", 
                "last_name": "Gareth Morgan, Prof.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint was the objective response rate (ORR) defined as the proportion of patients whose best responses were complete response (CR) and partial response (PR) (ORR = CR + PR).", 
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "Assessed  prior to each cycle for up to 12 cycles (24 weeks).  For patients achieving a complete or partial response, follow-up assessments were to be made 2, 8, 16, and 24 weeks after treatment was discontinued (up to ~48 wks)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851551"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of events and number and percentage of patients with treatment-emergent AEs that occurred from the time of first study treatment up to 30 days following the last study treatment were summarized by MedDRA system organ class and preferred term, NCI CTC grade, and relationship to study drug.\nSafety variables included adverse events, neurologic assessments, chemistry and hematology laboratory tests, physical examinations, and vital signs.\nNeurologic symptom scores were summarized for baseline and worst score on study. The number and percentage of patients with neurologic symptom abnormalities were tabulated and presented by severity and cycle for each symptom.\nNeurologic sign scores were summarized for baseline and worst score on study. The number and percentage of patients with neurologic sign abnormalities were tabulated and presented by severity and cycle for each sign.\nShifts from baseline to worst value were tabulated by cycle based on NCI CTC grades", 
                "measure": "Assessment of the number of events and number and percentage of patients with treatment-emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "AEs were assessed up to 30 days post last dose.  Dosing may last up to 24 weeks."
            }, 
            {
                "description": "Time To Progression (TTP), defined as the interval between the initial day of dosing and disease progression or death due to NHL", 
                "measure": "Time to Progression", 
                "safety_issue": "No", 
                "time_frame": "First dose to disease progression. Follow up was reported approximately every 3 months post-dose up to the date of patient death. Patients were followed up to  2 yrs."
            }, 
            {
                "description": "Overall Survival (OS) was defined as the interval between the initial day of dosing and death due to any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "The interval between first dose and death due to any cause.  Reported every 3 months post dose up to patient death. Follow up was approximately 2 years"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}